REFERENCES
1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76.
2. Saito A, Toyoda H, Kobayashi M, et al. Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning. Mod Pathol. 2021;34:417-25.
3. Singh SP, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma. J Clin Exp Hepatol. 2025;15:102446.
4. Chen S, Yuan B, Yu W, Wang X, He C, Chen C. Comparison of arterial infusion chemotherapy and chemoembolization for locally advanced hepatocellular carcinoma: a multicenter retrospective study. J Gastrointest Surg. 2022;26:2292-300.
5. Pan Y, Yuan Z, Wang J, et al. Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study. J Cancer Res Clin Oncol. 2023;149:14761-74.
6. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
7. Zhang W, Zhang K, Liu C, et al. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study. Front Immunol. 2023;14:1127349.
8. Tanaka T. Transarterial chemoembolization for hepatocellular carcinoma: current role and techniques. Interv Radiol. 2025;10:e20240016.
9. Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40:150-60.
10. He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5:953-60.
11. Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15:155-60.
12. Wang J, Zheng Z, Wu T, et al. Hepatic arterial infusion chemotherapy as a timing strategy for conversion surgery to treat hepatocellular carcinoma: a single-center real-world study. J Hepatocell Carcinoma. 2022;9:999-1010.
13. Zhu C, Ren X, Liu D, Zhang C. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology. 2021;460:152882.
14. Zheng K, Zhu X, Fu S, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303:455-64.
15. Yang M, Jiang X, Liu H, et al. Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis. Front Pharmacol. 2024;15:1410767.
16. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54-63.
17. Li H, Li R, Zhang X, et al. Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): a prospective, single-arm phase II study. JCO. 2025;43:e16212.
18. Zhao M, Lyu N, Zhong S, et al. 983P Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) - the DurHope study. Ann Oncol. 2023;34:S608.
19. Liu D, Mu H, Liu C, et al. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial. Neoplasma. 2023;70:811-8.
20. Xin Y, Cao F, Yang H, et al. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front Immunol. 2022;13:929141.
21. Pan L, Sun R, He Q, et al. Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: a prospective, single-arm phase II trial. J Clin Oncol. 2024;42:4103.
22. Zhao Z, Jiang X, Wen S, Hao Y. Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis. Front Pharmacol. 2024;15:1499269.
23. Liu G, Zhu D, He Q, et al. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for managing arterioportal shunt in hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study. J Hepatocell Carcinoma. 2024;11:1415-28.
24. Chen S, Shi F, Wu Z, et al. Hepatic arterial infusion chemotherapy plus lenvatinib and tislelizumab with or without transhepatic arterial embolization for unresectable hepatocellular carcinoma with portal vein tumor thrombus and high tumor burden: a multicenter retrospective study. J Hepatocell Carcinoma. 2023;10:1209-22.
25. Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68-77.
26. Luo L, Xiao Y, Zhu G, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a tertiary medical center experience. Front Oncol. 2022;12:1004652.
27. Zhang N, Zhang Y, Yu B, et al. Adjuvant HAIC combined with anlotinib and TQB2450 for resected high-risk hepatocellular carcinoma. Innovation. 2025;6:100910.
28. Lin ZP, Hu XL, Chen D, et al. Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma. World J Gastroenterol. 2024;30:2321-31.
29. Li R, Wang X, Li H, et al. Hepatic arterial infusion chemotherapy combined lenvatinib and PD-1 inhibitor showed improved survival for infiltrative hepatocellular carcinoma: a multicenter cohort study. J Hepatocell Carcinoma. 2024;11:1727-40.
30. Yang Y, Sun J, Cai J, et al.; Chinese Association of Liver Cancer and Chinese Medical Doctor Association. Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 Edition). Liver Cancer. 2025;14:311-33.
31. Zhang W, Zhao X, Gao W, et al. Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging. Front Immunol. 2025;16:1596864.
32. Nevola R, Ruocco R, Criscuolo L, et al. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol. 2023;29:1243-60.
33. Chi QY, Liu QY, Wang SJ, et al. Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study. BMC Cancer. 2025;25:1162.
34. Liu Y, Wang Y, Guo X, et al. Comparative effectiveness of adjuvant treatment for resected hepatocellular carcinoma: a systematic review and network meta-analysis. Front Oncol. 2021;11:709278.
35. Hu L, Zheng Y, Lin J, Shi X, Wang A. Does adjuvant hepatic artery infusion chemotherapy improve patient outcomes for hepatocellular carcinoma following liver resection? A meta-analysis. World J Surg Oncol. 2023;21:121.
36. Li SH, Mei J, Cheng Y, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study. J Clin Oncol. 2023;41:1898-908.
37. Wen Y, Lu L, Mei J, et al. Hepatic arterial infusion chemotherapy vs transcatheter arterial chemoembolization as adjuvant therapy following surgery for MVI-positive hepatocellular carcinoma: a multicenter propensity score matching analysis. J Hepatocell Carcinoma. 2024;11:665-78.
38. Long Y, Huang Z, He X, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy combined with donafenib in hepatocellular carcinoma with solitary large tumor and microvascular invasion: a multicenter, prospective, single-arm, phase II trial. J Clin Oncol. 2024;42:e16227.
39. Liang Y, Zhong D, Shang J, et al. Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysis. BMC Cancer. 2025;25:418.
40. Yang J, Jiang S, Chen Y, Zhang J, Deng Y. Adjuvant ICIs plus targeted therapies reduce HCC recurrence after hepatectomy in patients with high risk of recurrence. Curr Oncol. 2023;30:1708-19.
41. Ouyang J, Yang Y, Zhou Y, et al. Adjuvant camrelizumab plus apatinib in resected hepatocellular carcinoma with microvascular invasion: a multi-center real world study. Hepatobiliary Surg Nutr. 2024;13:616-31.
42. Singal AG, Yarchoan M, Yopp A, Sapisochin G, Pinato DJ, Pillai A. Neoadjuvant and adjuvant systemic therapy in HCC: current status and the future. Hepatol Commun. 2024;8:e0430.
43. Hu Z, Yang Z, Pan Y, et al. Survival benefit of preoperative hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin followed by hepatectomy for hepatocellular carcinoma. Front Pharmacol. 2023;14:1210835.
44. Pan Y, Mei J, Chen J, et al. Comparison between portal vein perfusion chemotherapy and neoadjuvant hepatic arterial infusion chemotherapy for resectable intermediate to advanced stage hepatocellular carcinoma. Ann Surg Oncol. 2022;29:2016-29.
45. Shi Y, Chen K, Li X, et al. Prognosis of neoadjuvant HAIC and lenvatinib followed by surgery versus direct resection for resectable or borderline resectable hepatocellular carcinoma: a real-world study. J Hepatocell Carcinoma. 2024;11:2063-76.
46. Tao P, Wei Y, Zhu G, et al. 187P Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero). Ann Oncol 2023;34:S1547-8. Available from: https://www.annalsofoncology.org/article/S0923. [Last accessed on 24 Apr 2026].
47. Wu X, Wang Y, Wang S, et al. Neoadjuvant targeted immunotherapy followed by surgical resection versus upfront surgery for hepatocellular carcinoma with macrovascular invasion: a multicenter study. J Cancer. 2024;15:3024-33.
48. Yuan Y, He W, Yang Z, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023;109:1222-30.
49. Zhao W, Liu C, Wu Y, et al. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience. Transl Cancer Res. 2024;13:2315-31.
50. Wu C, Dong Y, Li X, et al. TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden - a propensity-score matching comparative study. Front Immunol. 2025;16:1664756.
51. Yang J, Shang X, Li J, Wei N. Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2024;15:346-55.
52. Abza GB, De Vos K, Annaert P. Inhibition of ABC transporters by sorafenib and lenvatinib: implications for drug-induced cholestasis. Xenobiotica. 2025;55:99-109.
53. Hountondji L, Ferreira De Matos C, Lebossé F, et al. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep. 2023;5:100719.
54. Tang HH, Zhang MQ, Zhang ZC, et al. Prognostic nutritional index predicts survival in intermediate and advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with PD-(L)1 inhibitors and molecular targeted therapies. BMC Cancer. 2025;25:603.
55. Lv X, Zhang PB, Zhang EL, Yang S. Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: a comprehensive review. World J Surg Oncol. 2025;23:166.
56. Zhao Y, Huang F, Liu S, et al. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score. J Cancer Res Clin Oncol. 2023;149:5181-92.
57. Zhu AX, Dayyani F, Yen CJ, et al. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma. Clin Cancer Res. 2022;28:3537-45.
58. Li J, Yang B, Teng Z, Liu Y, Li D, Qu X. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis. Front Immunol. 2024;15:1430196.
